PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
18372398-4	2008	Oral BaP-treated Cyp1a1/1a2/1b1(-/-) mice showed the same "rescued" response as that seen in the Cyp1a1/1b1(-/-) mouse; we believe this reflects the absence of CYP1B1 in immune tissues.	Benzo(a)pyrene	5-8	cytochrome P450, family 1, subfamily b, polypeptide 1	Mus musculus	160-166	
23761301-6	2013	BaP-metabolizing CYP1B1 in the PSI and CYP3A59 in the PGD are the most likely candidates to participate in tumor initiation in the epithelial cells of these two tissues; oncogenes and tumor-suppressor genes upregulated and downregulated during tumorigenesis are completely different between these tissues.	Benzo(a)pyrene	0-3	cytochrome P450, family 1, subfamily b, polypeptide 1	Mus musculus	17-23	
19666105-5	2009	In addition, the BaP-induced CYP1A1 and 1B1 protein levels and BaP-elevated glutathione S-transferase (GST) activity were significantly higher in these transgenic cells, in parallel with elevated GSTp1, CYP1A1, and CYP1B1 mRNA levels, compared to wild-type MAECs.	Benzo(a)pyrene	17-20	cytochrome P450, family 1, subfamily b, polypeptide 1	Mus musculus	215-221	
18794127-11	2008	Benzo(a)pyrene (BP), which is similarly activated by Cyp1b1 in vitro, did not affect tumorigenesis in Min mice.	Benzo(a)pyrene	0-14	cytochrome P450, family 1, subfamily b, polypeptide 1	Mus musculus	53-59	
18794127-11	2008	Benzo(a)pyrene (BP), which is similarly activated by Cyp1b1 in vitro, did not affect tumorigenesis in Min mice.	Benzo(a)pyrene	16-18	cytochrome P450, family 1, subfamily b, polypeptide 1	Mus musculus	53-59	
17997381-1	2008	The CYP1A1, CYP1A2, and CYP1B1 enzymes are inducible by benzo[a]pyrene (BaP) and 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD); metabolism of BaP by these enzymes leads to electrophilic intermediates and genotoxicity.	Benzo(a)pyrene	56-70	cytochrome P450, family 1, subfamily b, polypeptide 1	Mus musculus	24-30	
17049425-7	2006	There was a significant basal expression of Cyp1b1 in the liver of all genotypes, and this expression was independent of the BP exposure.	Benzo(a)pyrene	125-127	cytochrome P450, family 1, subfamily b, polypeptide 1	Mus musculus	44-50	
15919055-9	2005	Cytochrome P450 1B1 (CYP1B1) mRNA, one of the genes activated by BaP, was present only in the groups exposed to BaP; the levels of CYP1B1 mRNA decreased in the presence of increasing concentrations of RANKL.	Benzo(a)pyrene	65-68	cytochrome P450, family 1, subfamily b, polypeptide 1	Mus musculus	0-19	
16307768-10	2006	Although TNFalpha and CYP1B1 are implicated as essential mediators of hypocellularity, the similar induction of TNFalpha mRNA and CYP1B1 mRNA in the BM by BP and DMBA suggests that they are not limiting factors in mediating the different effects of these PAHs.	Benzo(a)pyrene	155-157	cytochrome P450, family 1, subfamily b, polypeptide 1	Mus musculus	130-136	
16377763-0	2006	Oral benzo[a]pyrene in Cyp1 knockout mouse lines: CYP1A1 important in detoxication, CYP1B1 metabolism required for immune damage independent of total-body burden and clearance rate.	Benzo(a)pyrene	5-19	cytochrome P450, family 1, subfamily b, polypeptide 1	Mus musculus	84-90	
16377763-1	2006	CYP1A1 and CYP1B1 metabolically activate many polycyclic aromatic hydrocarbons (PAHs), including benzo[a]pyrene, to reactive intermediates associated with toxicity, mutagenesis, and carcinogenesis.	Benzo(a)pyrene	97-111	cytochrome P450, family 1, subfamily b, polypeptide 1	Mus musculus	11-17	
16377763-8	2006	Thus, a balance between tissue-specific expression of the CYP1A1 and CYP1B1 enzymes governs sensitivity of benzo[a]pyrene toxicity and, possibly, carcinogenicity.	Benzo(a)pyrene	107-121	cytochrome P450, family 1, subfamily b, polypeptide 1	Mus musculus	69-75	
15919055-9	2005	Cytochrome P450 1B1 (CYP1B1) mRNA, one of the genes activated by BaP, was present only in the groups exposed to BaP; the levels of CYP1B1 mRNA decreased in the presence of increasing concentrations of RANKL.	Benzo(a)pyrene	65-68	cytochrome P450, family 1, subfamily b, polypeptide 1	Mus musculus	21-27	
15919055-9	2005	Cytochrome P450 1B1 (CYP1B1) mRNA, one of the genes activated by BaP, was present only in the groups exposed to BaP; the levels of CYP1B1 mRNA decreased in the presence of increasing concentrations of RANKL.	Benzo(a)pyrene	65-68	cytochrome P450, family 1, subfamily b, polypeptide 1	Mus musculus	131-137	
15919055-9	2005	Cytochrome P450 1B1 (CYP1B1) mRNA, one of the genes activated by BaP, was present only in the groups exposed to BaP; the levels of CYP1B1 mRNA decreased in the presence of increasing concentrations of RANKL.	Benzo(a)pyrene	112-115	cytochrome P450, family 1, subfamily b, polypeptide 1	Mus musculus	0-19	
15919055-9	2005	Cytochrome P450 1B1 (CYP1B1) mRNA, one of the genes activated by BaP, was present only in the groups exposed to BaP; the levels of CYP1B1 mRNA decreased in the presence of increasing concentrations of RANKL.	Benzo(a)pyrene	112-115	cytochrome P450, family 1, subfamily b, polypeptide 1	Mus musculus	21-27	
15919055-9	2005	Cytochrome P450 1B1 (CYP1B1) mRNA, one of the genes activated by BaP, was present only in the groups exposed to BaP; the levels of CYP1B1 mRNA decreased in the presence of increasing concentrations of RANKL.	Benzo(a)pyrene	112-115	cytochrome P450, family 1, subfamily b, polypeptide 1	Mus musculus	131-137	
15667830-0	2005	Induction of CYP1A1 and CYP1B1 in liver and lung by benzo(a)pyrene and 7,12-d imethylbenz(a)anthracene do not affect distribution of polycyclic hydrocarbons to target tissue: role of AhR and CYP1B1 in bone marrow cytotoxicity.	Benzo(a)pyrene	52-66	cytochrome P450, family 1, subfamily b, polypeptide 1	Mus musculus	24-30	
15667830-11	2005	Effective delivery of BP to BM is indicated by formation of BP-quinone DNA adducts and the effective induction of CYP1B1.	Benzo(a)pyrene	22-24	cytochrome P450, family 1, subfamily b, polypeptide 1	Mus musculus	114-120	
35052622-11	2022	CYP1B1 plays a critical role in the metabolic activation of BP to DNA-reactive metabolites.	Benzo(a)pyrene	60-62	cytochrome P450, family 1, subfamily b, polypeptide 1	Mus musculus	0-6	
14613719-0	2003	Bone marrow cytotoxicity of benzo[a]pyrene is dependent on CYP1B1 but is diminished by Ah receptor-mediated induction of CYP1A1 in liver.	Benzo(a)pyrene	28-42	cytochrome P450, family 1, subfamily b, polypeptide 1	Mus musculus	59-65	
14613719-2	2003	Benzo(a)pyrene (BP), a much more potent Ah receptor ligand, shows very different responses that nevertheless depend on CYP1B1.	Benzo(a)pyrene	0-14	cytochrome P450, family 1, subfamily b, polypeptide 1	Mus musculus	119-125	
14613719-2	2003	Benzo(a)pyrene (BP), a much more potent Ah receptor ligand, shows very different responses that nevertheless depend on CYP1B1.	Benzo(a)pyrene	16-18	cytochrome P450, family 1, subfamily b, polypeptide 1	Mus musculus	119-125	
14613719-9	2003	Thus, hepatic metabolism may prevent BP from reaching the BM, where it can be bioactivated by CYP1B1.	Benzo(a)pyrene	37-39	cytochrome P450, family 1, subfamily b, polypeptide 1	Mus musculus	94-100	
12649394-0	2003	Role of cytochrome P4501B1 in benzo[a]pyrene bioactivation to DNA-binding metabolites in mouse vascular smooth muscle cells: evidence from 32P-postlabeling for formation of 3-hydroxybenzo[a]pyrene and benzo[a]pyrene-3,6-quinone as major proximate genotoxic intermediates.	Benzo(a)pyrene	30-44	cytochrome P450, family 1, subfamily b, polypeptide 1	Mus musculus	8-26	
12649394-8	2003	BP treatment of SMCs resulted in induction of aryl hydrocarbon hydroxylase (AHH) activity and CYP1B1, but not CYP1A1, apoprotein.	Benzo(a)pyrene	0-2	cytochrome P450, family 1, subfamily b, polypeptide 1	Mus musculus	94-100	
12649394-10	2003	In conclusion, the results of this study support the hypothesis that in SMCs, which are target sites for the development of atherosclerosis, the major bioactivation pathway of BP entails CYP1B1-mediated formation of the 3-OH-BP and BPQ, which are proximate genotoxic metabolites that may in turn get transformed to ultimate DNA-binding metabolites, which may contribute to atherogenesis by PAHs.	Benzo(a)pyrene	176-178	cytochrome P450, family 1, subfamily b, polypeptide 1	Mus musculus	187-193	
12628579-7	2003	For example, CYP1B1 was induced 9-fold and 10-fold by benzo[a]pyrene and 3,4,3",4"-tetrachlorobiphenyl in livers of male and female mice, respectively, whereas in testis and ovary, the fold induction of CYP1B1 by two inducers was only 1.1 and 1.4, respectively.	Benzo(a)pyrene	54-68	cytochrome P450, family 1, subfamily b, polypeptide 1	Mus musculus	13-19	
12628579-7	2003	For example, CYP1B1 was induced 9-fold and 10-fold by benzo[a]pyrene and 3,4,3",4"-tetrachlorobiphenyl in livers of male and female mice, respectively, whereas in testis and ovary, the fold induction of CYP1B1 by two inducers was only 1.1 and 1.4, respectively.	Benzo(a)pyrene	54-68	cytochrome P450, family 1, subfamily b, polypeptide 1	Mus musculus	203-209	
11741297-1	2001	Previous studies have shown that cytochrome P450 1A1 (CYP1A1), CYP1B1, and prostaglandin-endoperoxide synthase (PTGS2) are inducible by benzo[a]pyrene (BaP) and 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD, dioxin), and all three metabolize BaP to reactive DNA-binding intermediates and excreted products.	Benzo(a)pyrene	136-150	cytochrome P450, family 1, subfamily b, polypeptide 1	Mus musculus	63-69	
33800341-4	2021	Repeated oral administration of B[a]P led to, at the doses of 20 and 200 mg/kg/day, significant overexpression of Cyp1a1/Cyp1b1 in 2 out of the 3 brain regions considered, thereby suggesting the ability of the brain to metabolize B[a]P itself.	Benzo(a)pyrene	32-37	cytochrome P450, family 1, subfamily b, polypeptide 1	Mus musculus	121-127	
34216713-7	2021	Our results showed that 5-DMNB had a substantial inhibitory effect on CYP1B1 induced by BaP and upregulated the detoxification enzymes UDP-glucuronosyltransferases (UGTs) and glutathione S-transferases (GSTs).	Benzo(a)pyrene	88-91	cytochrome P450, family 1, subfamily b, polypeptide 1	Mus musculus	70-76	
29931584-9	2019	An increased expression of CYP1A1 in liver and colon and of CYP1B1 in liver of BaP-treated mice was seen, while RVT inhibited the extent of biotransformation mediated by these enzymes in the respective tissue samples.	Benzo(a)pyrene	79-82	cytochrome P450, family 1, subfamily b, polypeptide 1	Mus musculus	60-66	
32553695-4	2020	In BM, CYP1B1-mediated metabolism of 7, 12-dimethylbenz[a]anthracene (DMBA) suppresses HSPC colony formation within 6 h, whereas benzo(a)pyrene (BP) generates protective cytokines.	Benzo(a)pyrene	129-143	cytochrome P450, family 1, subfamily b, polypeptide 1	Mus musculus	7-13	
32553695-4	2020	In BM, CYP1B1-mediated metabolism of 7, 12-dimethylbenz[a]anthracene (DMBA) suppresses HSPC colony formation within 6 h, whereas benzo(a)pyrene (BP) generates protective cytokines.	Benzo(a)pyrene	145-147	cytochrome P450, family 1, subfamily b, polypeptide 1	Mus musculus	7-13	
25233930-2	2014	We have reported previously that coordinated upregulation of CYP1B1 by inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-alpha) and the aryl hydrocarbon receptor ligands, may increase bioactivation of promutagens, such as benzo[a]pyrene (BaP) in epithelial cells.	Benzo(a)pyrene	237-251	cytochrome P450, family 1, subfamily b, polypeptide 1	Mus musculus	61-67	
28007926-4	2017	BaP-induced Cyp1a1 and Cyp1b1 mRNA levels were higher 4 hours after dosing at noon than at 4 hours after dosing at midnight, and this corresponded with parallel changes in Per gene expression.	Benzo(a)pyrene	0-3	cytochrome P450, family 1, subfamily b, polypeptide 1	Mus musculus	23-29	
28007926-6	2017	Analysis of CYP1A1 and CYP1B1 gene expression showed the maximum enzyme-induced metabolism response 12 and 20 hours after shock, as determined by ethoxyresorufin-O-deethylase activity, metabolism of BaP, and formation of DNA-BaP adducts.	Benzo(a)pyrene	199-202	cytochrome P450, family 1, subfamily b, polypeptide 1	Mus musculus	23-29	
28007926-6	2017	Analysis of CYP1A1 and CYP1B1 gene expression showed the maximum enzyme-induced metabolism response 12 and 20 hours after shock, as determined by ethoxyresorufin-O-deethylase activity, metabolism of BaP, and formation of DNA-BaP adducts.	Benzo(a)pyrene	225-228	cytochrome P450, family 1, subfamily b, polypeptide 1	Mus musculus	23-29	
28007926-7	2017	The pattern of PER-, BMAL-, and aryl hydrocarbon receptor-induced P450 gene expression and BaP metabolism was similar to BaP-induced Cyp1A1 and Cyp1B1 and molecular clock gene expression in mouse mammary glands.	Benzo(a)pyrene	121-124	cytochrome P450, family 1, subfamily b, polypeptide 1	Mus musculus	144-150	
26215100-4	2015	A set of 63 genes was identified (the AhR gene expression biomarker) that was dependent on AhR for regulation after exposure to TCDD or benzo[a]pyrene and includes the known AhR targets Cyp1a1 and Cyp1b1.	Benzo(a)pyrene	136-150	cytochrome P450, family 1, subfamily b, polypeptide 1	Mus musculus	197-203	
30165701-2	2018	In this study, using Cyp1b1-/-, Cyp1a1/1a2-/-, and Cyp1a1/1a2/1b1-/- mice, we observed that cigarette and environmental toxins, namely benzo[a]pyrene (BaP) and 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), induce pancreatic mitochondrial respiratory dysfunction and pancreatitis.	Benzo(a)pyrene	135-149	cytochrome P450, family 1, subfamily b, polypeptide 1	Mus musculus	21-27	
25233930-2	2014	We have reported previously that coordinated upregulation of CYP1B1 by inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-alpha) and the aryl hydrocarbon receptor ligands, may increase bioactivation of promutagens, such as benzo[a]pyrene (BaP) in epithelial cells.	Benzo(a)pyrene	253-256	cytochrome P450, family 1, subfamily b, polypeptide 1	Mus musculus	61-67	
25233930-6	2014	The inhibition of the P-TEFb subunit, cyclin-dependent kinase 9 (CDK9), which phosphorylates RNA polymerase II (RNAPII), prevented the enhanced CYP1B1 induction by a combination of BaP and inflammatory cytokine.	Benzo(a)pyrene	181-184	cytochrome P450, family 1, subfamily b, polypeptide 1	Mus musculus	144-150	
25233930-7	2014	Furthermore, using chromatin immunoprecipitation assays, we found that cotreatment of epithelial cells with TNF-alpha and BaP resulted in enhanced recruitment of both CDK9 and RNAPII to the Cyp1b1 gene promoter.	Benzo(a)pyrene	122-125	cytochrome P450, family 1, subfamily b, polypeptide 1	Mus musculus	190-196	
24497629-4	2014	Benzo[a]pyrene (BaP) treatment induced oxidative stress, mitochondrial respiratory defects, and mtDNA damage that was attenuated by a CYP1B1-specific inhibitor, 2,3,4,5-tetramethoxystilbene.	Benzo(a)pyrene	0-14	cytochrome P450, family 1, subfamily b, polypeptide 1	Mus musculus	134-140	
24497629-4	2014	Benzo[a]pyrene (BaP) treatment induced oxidative stress, mitochondrial respiratory defects, and mtDNA damage that was attenuated by a CYP1B1-specific inhibitor, 2,3,4,5-tetramethoxystilbene.	Benzo(a)pyrene	16-19	cytochrome P450, family 1, subfamily b, polypeptide 1	Mus musculus	134-140	
24497629-6	2014	Administration of benzo[a]pyrene or 2,3,7,8-tetrachlorodibenzodioxin induced similar mitochondrial functional abnormalities and oxidative stress in the lungs of wild-type mice and Cyp1a1/1a2-null mice, but the effects were markedly blunted in Cyp1b1-null mice.	Benzo(a)pyrene	18-32	cytochrome P450, family 1, subfamily b, polypeptide 1	Mus musculus	243-249